Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1837 - First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma (582P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Eriko Fujimoto

Citation

Annals of Oncology (2017) 28 (suppl_10): x177-x182. 10.1093/annonc/mdx668

Authors

E. Fujimoto1, K. Kuribayashi1, S. Kanemura1, Y. Negi1, Y. Koda1, K. Mikami1, T. Minami1, T. Yokoi2, T. Nakano3, T. Kijima1

Author affiliations

  • 1 Division Of Respiratory Medicine, Department Of Internal Medicine, Hyogo College of Medicine, 663-8501 - Nishinomiya, Hyogo/JP
  • 2 Thoracic Oncology, Hyogo College of Medicine, 663-8501 - Nishinomiya, Hyogo/JP
  • 3 Center For Respiratory Diseases, Otemae Hospital, 540-0008 - Osaka/JP
More

Resources

Abstract 1837

Background

Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates the efficacy of first-line systemic pemetrexed and cisplatin chemotherapy in MPeM.

Methods

Twenty-four patients with histologically proven MPeM were treated with pemetrexed plus cisplatin as first-line systemic chemotherapy. Response was evaluated radiologically according to standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Twenty-two patients underwent 18F-fluorodeoxyglucose positron emission tomography/(FDG-PET)/computed tomography (CT) at baseline, and 13 were eligible for metabolic assessment.

Results

Two complete responses and 9 partial responses were achieved. Overall response rate and disease control rate were 45.8% and 91.7%, respectively. Median progression-free survival and median overall survival were 11.0 months and 15.8 months, respectively. Wet- type MPeM had significantly longer survival (40.9 months median) than other clinical types (15.5 months) (P = 0.045). Baseline maximum standardized uptake value in 22 patients was 8.93 (range, 2.5–16.77).

Conclusions

Systemic pemetrexed plus cisplatin is active for MPeM. Disparity with the outcome of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) needs to receive more emphasis, since peritoneal mesothelioma has 5-year survival rate of 50%.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings